Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug Profile

Dusigitumab - AstraZeneca

Alternative Names: MEDI-573

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Liver cancer; Solid tumours

Most Recent Events

  • 28 Jun 2019 MedImmune completes a phase Ib/II trial for Breast cancer (Combination therapy, Metastatic disease) in USA, Canada, Bahamas, United Kingdom, Belgium, France, Germany, Hungary, Poland, Spain & Israel (IV) (NCT01446159)
  • 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)
  • 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) due to safety and efficacy issues before February 2018 (MedImmune pipeline, February 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

UPDATED: What’s Holding Back Clinical Trials? Tell Us.

We have updated the survey link due to an issue with the original one. We’re conducting a short survey to uncover the biggest challenges and frustrations professionals face when planning clinical trials and we want to hear from you. Whatever you're involved in clinical trial planning, your experience is invaluable. The survey takes less than 5 minutes and responses are confidential. Thank you for helping us advance smarter, more efficient clinical development.

Take Survey